A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors	Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gonadal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, metastatic malignant neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, respiratory system disorder, respiratory tract neoplasm, skin disorder, stomach disorder, uterine disorder	Active, not recruiting	Phase 1	2026-06-22		NCT05143970

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Innate Pharma	5
Institut Paoli-Calmettes	60

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Institut Paoli Calmettes	Marseille	France	49